BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859.
J Immunother Cancer. 2022.
PMID: 36096532
Free PMC article.